zolpidem AMBIEN

Class: Nonbenzodiazepine/​Imidazopyridine
FDA Indications: Short-term Treatment Of Insomnia
Off-Label Use: Jet Lag, Analgesia
Prescribing
FDA Schedule IV
Forms: 5, 10mg tablet; 6.25, 12.5mg CR tablet; 1.75, 3.5mg sublingual tab (Intermezzo)
Dose Range: 10-20 mg/day
Starting: 10 mg qhs; recommend start at 5 mg for women, elderly, patients with lower body weight. PDR lists maximum dose of 10 mg, but in practice many patients require and tolerate 20 mg QHS dosing.
Stopping: Taper to avoid rebound insomnia

NAMI drug fact sheet

Precautions
Contraindications: None, other than patients with known hypersensitivity to zolpidem
Serious Side Effects: Anterograde amnesia; somnambulism (0.3-1%), sleep related eating and sleep-driving
Side Effects: dizziness, nausea, amnesia, amnesia, daytime somnolence
Pharmacodynamics
1° MOA: GABAAR α1 subunit agonist
Target: GABAA α1
Pharmacokinetics
t½: 2.5 (1.4-4.5)° TMAX: 1.5°
Absorption Rate: Rapid
Substrate of: 3A4, 2C9; 1A2
Inhibits: ∅ ; Induces:
Active Metabolites:
DDIs
Misc
  • - preserves normal sleep architecture
  • - preferential binding of GABAAR α1 subunits > α23 subunits → sedation > anxiolysis
Special Populations

Category C—Crosses the placenta. No studies in pregnant women.

RID 4.7-19.1%; ∅ AE's have been reported in exposed infants

Start at 5mg to ↓ chances of motor and/or cognitive impairment

No dosage adjustment necessary.


↓ dose to 5 mg qhs for hepatically impaired

logo

Developed & Designed by Kevin M. Nasky, D.O. • Built with Bootstrap, PHP & MySQL • Hosted by SiteGround
Last updated December 05 2018 19:19:12. Disclaimer: This website does not provide medical advice, nor is it a substitute for clinical judgment.